PMID- 37546236
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230808
IS  - 1939-4551 (Print)
IS  - 1939-4551 (Electronic)
IS  - 1939-4551 (Linking)
VI  - 16
IP  - 7
DP  - 2023 Jul
TI  - Update meta-analysis on the efficacy and safety issues of fexofenadine.
PG  - 100795
LID - 10.1016/j.waojou.2023.100795 [doi]
LID - 100795
AB  - BACKGROUND: Fexofenadine emerged as one of the most representative second 
      generation histamine H1 antagonist drugs since the 1990s, with an outstanding 
      efficacy and appreciable safety for the treatment of allergic patients. While 
      allergic rhino-conjunctivitis represents the most frequent atopic disease 
      globally, an update of fexofenadine efficacy and safety on this entity was 
      proposed as a surrogate of allergic condition. METHODS: Double blind, placebo 
      controlled, randomized clinical trials investigating the efficacy and safety of 
      fexofenadine for the treatment of Allergic Rhinitis were searched in 5 major 
      global databases. Eligibility criteria and characteristics, risk of bias, and 
      validity assessment, data extraction and heterogeneity evaluation are described. 
      Primary outcome selected corresponded to 12-reflective and instantaneous total 
      symptom scores (TSS), besides morning instantaneous TSS and the frequency of 
      reported adverse events (AEs); analysis was planned on the intention-to-treat 
      population.Standardized mean differences of scoring systems were analyzed, and 
      Cochran's Q statistic test and the I(2) test were assessed for heterogeneity. 
      RESULTS: From the initial 83 identified records, 12 eligible studies were 
      selected. In the evaluated patients, individuals receiving fexofenadine (1910) 
      showed a significant reduction of TSS compared with those who received placebo 
      (1777), change from baseline: standardized mean difference (SMD) -0.33; 95% 
      CI-0.47 to -0.18, p < 0.0001. Morning instantaneous TSS also demonstrated lower 
      symptoms (change from baseline: SMS -1.42; 95% CI -2.22 to -0.62, p = 0.0005). 
      Heterogeneity was found across selected studies.Frequency of AEs was similar 
      compared to placebo (OR = 1.04; 0.88-1.21), with no detection of heterogeneity 
      across these 12 studies. CONCLUSIONS: According to this new evidence, 
      fexofenadine maintains its beneficial profile on signs and symptoms of patients 
      with allergic conditions, as well as its attributes as one of the major 
      candidates for an ideal antihistamine medication (including special conditions 
      such as pregnancy and pre-school age), providing support to its over-the-counter 
      condition in several countries.
CI  - (c) 2023 The Author(s).
FAU - Gomez, Rene Maximiliano
AU  - Gomez RM
AD  - Argentinean Association of Allergy & Clinical Immunology (AAAeIC), Argentina.
AD  - Ayre Foundation, Salta, Argentina.
FAU - Moreno, Pablo
AU  - Moreno P
AD  - Argentinean Association of Allergy & Clinical Immunology (AAAeIC), Argentina.
FAU - Compalati, Enrico
AU  - Compalati E
AD  - Casa di Cura Villa Serena, GVM Care & Research, Genoa, Italy.
FAU - Canonica, Giorgio Walter
AU  - Canonica GW
AD  - Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 
      4, 20090, Pieve Emanuele, Milan, Italy.
AD  - Asthma & Allergy Unit-IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, 
      Milan, Rozzano, Italy.
FAU - Ansotegui Zubeldia, Ignacio Javier
AU  - Ansotegui Zubeldia IJ
AD  - Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, 
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20230711
PL  - United States
TA  - World Allergy Organ J
JT  - The World Allergy Organization journal
JID - 101481283
PMC - PMC10401337
OTO - NOTNLM
OT  - Efficacy
OT  - Fexofenadine
OT  - Histamine H1 antagonist
OT  - Non sedating
OT  - Safety
COIS- Authors declare to have no conflict of interest regarding the present 
      publication.
EDAT- 2023/08/07 06:42
MHDA- 2023/08/07 06:43
PMCR- 2023/07/11
CRDT- 2023/08/07 04:34
PHST- 2023/02/07 00:00 [received]
PHST- 2023/05/17 00:00 [revised]
PHST- 2023/06/15 00:00 [accepted]
PHST- 2023/08/07 06:43 [medline]
PHST- 2023/08/07 06:42 [pubmed]
PHST- 2023/08/07 04:34 [entrez]
PHST- 2023/07/11 00:00 [pmc-release]
AID - S1939-4551(23)00055-8 [pii]
AID - 100795 [pii]
AID - 10.1016/j.waojou.2023.100795 [doi]
PST - epublish
SO  - World Allergy Organ J. 2023 Jul 11;16(7):100795. doi: 
      10.1016/j.waojou.2023.100795. eCollection 2023 Jul.